{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T03:02:56Z","timestamp":1788404576757,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T00:00:00Z","timestamp":1710374400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.esmoop.2024.102996","type":"journal-article","created":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T20:46:29Z","timestamp":1712954789000},"page":"102996","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Treatment of patients with BRAF-mutated metastatic colorectal cancer after progression to encorafenib and cetuximab: data from a real-world nationwide dataset"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1036-5869","authenticated-orcid":false,"given":"M.M.","family":"Germani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6943-2897","authenticated-orcid":false,"given":"G.","family":"Vetere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1214-9342","authenticated-orcid":false,"given":"F.","family":"Santamaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Intini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Ghelardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5647-0525","authenticated-orcid":false,"given":"M.","family":"Bensi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7242-4396","authenticated-orcid":false,"given":"A.","family":"Boccaccino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Minelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2846-2517","authenticated-orcid":false,"given":"M.","family":"Carullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3791-6288","authenticated-orcid":false,"given":"P.","family":"Cirac\u00ec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7099-240X","authenticated-orcid":false,"given":"A.","family":"Passardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Santucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7344-0590","authenticated-orcid":false,"given":"R.","family":"Giampieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Persano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Fenocchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2492-4043","authenticated-orcid":false,"given":"A.","family":"Puccini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7593-8138","authenticated-orcid":false,"given":"S.","family":"Lonardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8530-8420","authenticated-orcid":false,"given":"F.","family":"Pietrantonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3864-0719","authenticated-orcid":false,"given":"L.","family":"Salvatore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Cremolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.esmoop.2024.102996_bib1","first-page":"660","article-title":"BRAF mutant colorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapies","volume":"6","author":"Clarke","year":"2015","journal-title":"J\u00a0Gastrointest Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2024.102996_bib2","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1038\/bjc.2015.142","article-title":"BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection","volume":"112","author":"Schirripa","year":"2015","journal-title":"Br J Cancer"},{"issue":"10","key":"10.1016\/j.esmoop.2024.102996_bib3","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/jnci\/djab042","article-title":"BRAF V600E mutation in first-line metastatic colorectal cancer: an analysis of individual patient data from the ARCAD database","volume":"113","author":"Cohen","year":"2021","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"23","key":"10.1016\/j.esmoop.2024.102996_bib4","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.esmoop.2024.102996_bib5","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S1470-2045(22)00197-8","article-title":"Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study","volume":"23","author":"Diaz","year":"2022","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2024.102996_bib6","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2024.102996_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100603","article-title":"Real-world first-line treatment of patients with BRAFV600E-mutant metastatic colorectal cancer: the CAPSTAN CRC study","volume":"7","author":"Martinelli","year":"2022","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.esmoop.2024.102996_bib8","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s41416-020-01089-9","article-title":"Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO","volume":"124","author":"Rossini","year":"2021","journal-title":"Br J Cancer"},{"issue":"17","key":"10.1016\/j.esmoop.2024.102996_bib9","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer","volume":"381","author":"Kopetz","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.esmoop.2024.102996_bib10","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1200\/JCO.20.02088","article-title":"Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON Study","volume":"39","author":"Tabernero","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"9863","key":"10.1016\/j.esmoop.2024.102996_bib11","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.esmoop.2024.102996_bib12","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer","volume":"372","author":"Mayer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2024.102996_bib13","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","article-title":"Trifluridine\u2013tipiracil and bevacizumab in refractory metastatic colorectal cancer","volume":"388","author":"Prager","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2024.102996_bib14","series-title":"SO-29 clinical characteristics, efficacy, and safety in patients receiving second- or third-line encorafenib plus cetuximab (E+C) vs control for metastatic colorectal cancer (mCRC): BEACON CRC post hoc analysis","first-page":"S174","volume":"34","author":"Tabernero","year":"2023"},{"key":"10.1016\/j.esmoop.2024.102996_bib15","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/j.annonc.2023.04.079","article-title":"P-23 clinical outcomes of encorafenib, binimetinib, and cetuximab for pretreated BRAF V600E-mutant metastatic colorectal cancer in the BEACON EAP follow-up study","volume":"34","author":"Kato","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2024.102996_bib16","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejca.2022.04.019","article-title":"Treatments after second progression in metastatic colorectal cancer: a pooled analysis of the TRIBE and TRIBE2 studies","volume":"170","author":"Rossini","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2024.102996_bib17","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejca.2019.06.008","article-title":"A\u00a0validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the \u201cBRAF BeCool\u201d study","volume":"118","author":"Loupakis","year":"2019","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.esmoop.2024.102996_bib18","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.annonc.2023.02.016","article-title":"Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments","volume":"34","author":"Ros","year":"2023","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2024.102996_bib19","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1038\/s41591-022-01976-z","article-title":"RNF43 mutations predict response to anti-BRAF\/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer","volume":"28","author":"Elez","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.esmoop.2024.102996_bib20","doi-asserted-by":"crossref","first-page":"S681","DOI":"10.1016\/j.annonc.2022.07.454","article-title":"316O Genomic mechanisms of acquired resistance of patients (pts) with BRAF V600E-mutant (mt) metastatic colorectal cancer (mCRC) treated in the BEACON study","volume":"33","author":"Kopetz","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2024.102996_bib21","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1200\/PO.21.00107","article-title":"Targeting secondary and tertiary resistance to BRAF inhibition in BRAF V600E\u2013mutated metastatic colorectal cancer","volume":"5","author":"Akhoundova","year":"2021","journal-title":"JCO Precis Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2024.102996_bib22","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1158\/1078-0432.CCR-22-3094","article-title":"A\u00a0phase Ib\/II trial of combined BRAF and EGFR inhibition in BRAF V600E positive metastatic colorectal cancer and other cancers: the EVICT (erlotinib and vemurafenib in combination trial) study","volume":"29","author":"Tan","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.esmoop.2024.102996_bib23","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1001\/jamaoncol.2018.5080","article-title":"Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical trial","volume":"5","author":"Cremolini","year":"2019","journal-title":"JAMA Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2024.102996_bib24","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1038\/s41591-022-01886-0","article-title":"Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial","volume":"28","author":"Sartore-Bianchi","year":"2022","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.esmoop.2024.102996_bib25","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.clcc.2021.12.001","article-title":"Rechallenge with BRAF and anti-EGFR inhibitors in patients with metastatic colorectal cancer harboring BRAFV600E mutation who progressed on cetuximab and encorafenib with or without binimetinib: a case series","volume":"21","author":"Ji","year":"2022","journal-title":"Clinical Colorectal Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2024.102996_bib26","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.annonc.2023.10.120","article-title":"Circulating tumor DNA, and clinical features to guide rechallenge with BRAF inhibitors in BRAF-V600E mutated metastatic colorectal cancer","volume":"35","author":"Ros","year":"2024","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2024.102996_bib27","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.annonc.2023.10.129","article-title":"Updated treatment recommendation for third-line treatment in advanced colorectal cancer from the ESMO Metastatic Colorectal Cancer Living Guideline","volume":"35","author":"Cervantes","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2024.102996_bib28","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1200\/JCO.2023.41.4_suppl.119","article-title":"BREAKWATER safety lead-in (SLI): Encorafenib (E)\u00a0+ cetuximab (C)\u00a0+ chemotherapy for BRAFV600E metastatic colorectal cancer (mCRC)","volume":"41","author":"Kopetz","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 4","key":"10.1016\/j.esmoop.2024.102996_bib29","article-title":"TRIDENTE trial: a phase II study of rechallenge with encorafenib, binimetinib, and cetuximab in patients with RAS wild-type\/BRAF V600E\u2013mutant metastatic colorectal cancer","volume":"41","author":"Kotani","year":"2023","journal-title":"JCO"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924007646?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924007646?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T09:31:12Z","timestamp":1714469472000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702924007646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S2059702924007646"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.102996","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of patients with BRAFV600E-mutated metastatic colorectal cancer after progression to encorafenib and cetuximab: data from a real-world nationwide dataset","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.102996","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"102996"}}